ASH presentation shows earlier treatment boosts efficacy of Imbruvica

11 December 2017
ash-logo-big

In an oral presentation at the ongoing American Society of Hematology (ASH) meeting, Johnson & Johnson’s (NYSE: JNJ) pharmaceutical arm Janssen has put forward a new analysis of data from Phase II and III studies of Imbruvica (ibrutinib).

The data show patients with relapsed/refractory mantle cell lymphoma (MCL) that were treated with Imbruvica earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability.

Imbruvica is a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, jointly developed and commercialized by Janssen and Pharmacyclics, an AbbVie (NYSE: ABBV) subsidiary.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical